Previous 10 | Next 10 |
Curis, Inc. (CRIS) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Conference Call Participants Presentation Operator Good afternoon everyone...
LEXINGTON, Mass. , May 5, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2020 financial results on Tuesday, Ma...
The following slide deck was published by Curis, Inc. in conjunction with this Read more ...
LEXINGTON, Mass. , April 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will present at the...
Curis Inc. (CRIS) Q4 2019 Earnings Conference Call March 19, 2020 04:30 PM ET Company Participants Bill Steinkrauss - CFO James Dentzer - President and CEO Robert Martell - Head, R&D Conference Call Participants Soumit Roy - JonesTrading A.J. Rashid - Columbia Threadn...
Curis (NASDAQ: CRIS ): Q4 GAAP EPS of -$0.26. More news on: Curis, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LEXINGTON, Mass. , March 19, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2019 . ...
LEXINGTON, Mass. , March 12, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2019 financial resul...
LEXINGTON, Mass. , Feb. 27, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $3...
LEXINGTON, Mass. , Feb. 6, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an amendment of its collaboration, license and option agreem...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...